A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Hepatic Steatosis and Elevated Liver Stiffness
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs GS 0976 (Primary) ; GS 9674 (Primary) ; Selonsertib (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Proof of concept
- Sponsors Gilead Sciences
- 17 Nov 2017 Planned number of patients changed from 110 to 120.
- 01 Sep 2017 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
- 01 Sep 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Apr 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History